The pharmacotherapeutic management of episodic and chronic migraine with gepants

References

• Headache Classification Committee of the International Headache Society (IHS). The international classified, 3rd editionation of headache disorders. Cephalalgia. 2018;38:1–211.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDN, Nichols E, Alam T. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:459–480.
   PubMed Web of Science ®Google Scholar
• Diseases GBD, Injuries C, Abbafati C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–350.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Nyari A, et al. CGRP and CGRP-Receptor as targets of migraine therapy: brain prize-2021. CNS Neurol Disord Drug Targets. 2022;21:460–478.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014;137:650–651.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR. An update: pathophysiology of migraine. Neurol Clin. 2019;37:651–671.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8:2. DOI:10.1038/s41572-021-00328-4
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, Do TP, et al. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18:795–804.
   PubMed Web of Science ®Google Scholar
• Durham PL. CGRP-receptor antagonists–a fresh approach to migraine therapy? N Engl J Med. 2004;350:1073–1075.
   PubMed Web of Science ®Google Scholar
• Scuteri D, Tonin P, Nicotera P, et al. Real world considerations for newly approved CGRP receptor antagonists in migraine care. Expert Rev Neurother. 2022;22:221–230.
   PubMed Web of Science ®Google Scholar
• Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62:1153–1163. DOI:10.1111/head.14389
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737–745. DOI:10.1016/S0140-6736(19)31606-X
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51–60. DOI:10.1016/S0140-6736(20)32544-7
   PubMed Web of Science ®Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230–2241. DOI:10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887–1898.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706. DOI:10.1056/NEJMoa2035908
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(Suppl 9):23–33.
   PubMedGoogle Scholar
• Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(4):221–235. DOI:10.1111/head.12601
   PubMedGoogle Scholar
• Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397:1505–1518.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91:e2222–2232.
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS. Board of directors of the American headache, S. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–1039.
   PubMed Web of Science ®Google Scholar
• Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23:133.
   PubMed Web of Science ®Google Scholar
• Ambat FDF, Bentivegna E, Martelletti P. Novel migraine therapies may reduce public and personal disadvantages for people with migraine. BioDrugs. 2022;36:337–339.
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Onan D, Martelletti P. Unmet needs in preventive treatment of migraine. Neurol Ther. 2023;12:337–342.
   PubMed Web of Science ®Google Scholar
• Chowdhury D, Mundra A, Datta D, et al. Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: a randomized controlled trial. Cephalalgia. 2022;42:859–871.
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022;11. DOI:10.3390/jcm11061656
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142–149.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019;39:1753–1761.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2021;41:546–560.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Efficacy of ubrogepant based on prior exposure and response to triptans: a post hoc analysis. Headache. 2021;61:422–429.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Singh RBH, Revicki DA, et al. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022;23:50.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60:141–152.
   PubMed Web of Science ®Google Scholar
• Jakate A, Boinpally R, Butler M, et al. Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache. 2020;60:1340–1350.
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61:642–652.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Goadsby PJ, et al. Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology. 2022;99:e1905–1915.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen M, Sun Y, et al. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34:463–471. DOI:10.1007/s40263-020-00715-7
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shu Y, Diao Y, et al. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: a meta-analysis. Medicine (Baltimore). 2021;100:e24741.
   PubMed Web of Science ®Google Scholar
• Wu SZ, Chen L. Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies. Int J Neurosci. 2022:1–7. DOI:10.1080/00207454.2022.2090351
   Google Scholar
• Johnston KM, Powell L, Popoff E, et al. Ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat/harm. Clin J Pain. 2022;38:680–685. DOI:10.1097/AJP.0000000000001072
   PubMed Web of Science ®Google Scholar
• Chiang CC, Arca KN, Dunn RB, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61:620–627. DOI:10.1111/head.14062
   PubMed Web of Science ®Google Scholar
• Murray AM, Stern JI, Robertson CE, et al. Real-world patient experience of CGRP-Targeting therapy for migraine: a narrative review. Curr Pain Headache Rep. 2022;26:783–794.
   PubMed Web of Science ®Google Scholar
• The International headache congress - IHS and EHF joint congress 2021: virtual. 8-12 September 2021. J Headache Pain. 2021;22:103. DOI:10.1186/s10194-021-01293-9
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125.
   PubMed Web of Science ®Google Scholar
• Popoff E, Johnston K, Croop R, et al. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. Headache. 2021;61:906–915.
   PubMed Web of Science ®Google Scholar
• Johnston KM, L’Italien G, Popoff E, et al. Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant. Adv Ther. 2021;38:5209–5220.
   PubMed Web of Science ®Google Scholar
• IHC 2019. Abstracts. Cephalalgia. 2019;39:1–337.
   Web of Science ®Google Scholar
• Johnston K, Harris L, Powell L, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23:10.
   PubMed Web of Science ®Google Scholar
• Baker TE, Croop R, Kamen L, et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med. 2022;17:277–282.
   PubMed Web of Science ®Google Scholar
• Woodhead JL, Siler SQ, Howell BA, et al. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022;188:108–116.
   PubMed Web of Science ®Google Scholar
• Chan TLH, Cowan RP, Woldeamanuel YW. Calcitonin gene-related peptide receptor antagonists (gepants) for the acute treatment of nausea in episodic migraine: a systematic review and meta-analysis. Headache. 2020;60:1489–1499.
   PubMed Web of Science ®Google Scholar
• Ha DK, Kim MJ, Han N, et al. Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated meta-analysis. Clin Drug Investig. 2021;41:119–132.
   PubMed Web of Science ®Google Scholar
• Lee S, Staatz CE, Han N, et al. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78:1365–1376.
   PubMed Web of Science ®Google Scholar
• Huang T, Xu Y, Chen Y, et al. Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: a meta-analysis. Brain Behav. 2022;12:e2542.
   PubMed Web of Science ®Google Scholar
• Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2128544. DOI:10.1001/jamanetworkopen.2021.28544
   PubMed Web of Science ®Google Scholar
• Polavieja P, Belger M, Venkata SK, et al. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings. J Headache Pain. 2022;23:76.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19:727–737. DOI:10.1016/S1474-4422(20)30234-9
   PubMed Web of Science ®Google Scholar
• Powell LC, L’Italien G, Popoff E, et al. Health state utility mapping of rimegepant for the preventive treatment of migraine: double-blind treatment phase and open label extension (BHV3000-305). Adv Ther. 2022. DOI:10.1007/s12325-022-02369-x
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Lipton RB, Ailani J, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42:3–11.
   PubMed Web of Science ®Google Scholar
• Boinpally R, Spaventa J, Chen K, et al. Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: a randomized trial. Clin Drug Investig. 2021;41:557–567.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Boinpally R, De Abreu Ferreira R, et al. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache. 2023. DOI:10.1111/head.14433
   Web of Science ®Google Scholar
• Ankrom W, Xu J, Vallee MH, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female participants. J Clin Pharmacol. 2020;60:1157–1165.
   PubMed Web of Science ®Google Scholar
• Tao X, Yan Z, Meng J, et al. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain. 2022;23:19.
   PubMed Web of Science ®Google Scholar